Industry News

newsicon-industry

News from the global pharmaceuticals industry about head lice treatments and corporate developments, including takeovers and mergers.

10.11.20 | Oystershell acquires Rid Brand

Oystershell has come to an agreement with Bayer HealthCare LLC to acquire RID®, one of the leading brands in lice treatment in the US. 

RID® is known for its strong consumer brand awareness, high levels of professional endorsement and its well-respected brand logo and attributes.  In 2019, RID® achieved 25 million USD in retail sales and is the #2 brand in the US lice treatment market.

10.11.20 | FDA Approve Sklice

The U.S. Food and Drug Administration has approved Sklice to treat head lice for nonprescription, or over-the-counter (OTC) use. The FDA initially approved Sklice (ivermectin) lotion, 0.5% for the treatment of head lice infestation in patients 6 months of age and older as a prescription drug in February 2012.

09.01.19 | Resultz Distributors appointed in Germany

Nuvo Pharmaceuticals have entered into an agreement with Heumann Pharma & Co GmBH Generica KC (Heumann) for the exclusive right to distribute, market and sell Resultz in Germany. Headquarterd in Nuremberg, Heumann is part of the Torrent Pharma Group.

04.05.18 | NUVO PHARMACEUTICALS ORDINARY SHARES (NRIFF) SI Increased By 1540%

A report by Jan Rainey published on April 29th 2018, suggests that NUVO PHARMACEUTICALS INC ORDINARY SHARES (OTCMKTS: NRIFF) had an increase of 1540% in short interest.

11.01.18 | Nuvo Pharmaceuticals acquires global rights for Head Lice Treatment

Nuvo Pharmaceuticals announced that it had acquired the global rights for Resultz, a head lice treatment from Piedmont Pharmaceuticals.

15.12.17 | Alliance Pharma buys the head lice treatment Vamousse from Tyra Tech for $13m.

The speciality pharmaceutical company, Alliance Pharma has added Vamousee to its portfolio after agreeing to buy the pesticide-free head lice treatment from Tyra Tech for $13m (£9.6m).

15.12.17 | Safety, Efficacy, and Physicochemical Characterization of T. crispa Ointment

A new study investigating a community-based pediculicidal ointment, Tinospora crispa, has revealed that T. crispa pediculicidal ointment is safe, effective and has acceptable physicochemical characteristics.

22.02.17 | Assessment of oral ivermectin versus shampoo in the treatment of pediculosis

A study conducted in two neighbouring villages of Sine-Saloum, Senagal, analysed the effect of using oral Ivermectin and shampoo in the treatment of pediculosis and revealed that whilst oral ivermectin is more highly effective in treating pediculosis compared with shampoo, ivermectin resitance may emerge during treatment.

15.05.17 | A randomized clinical study comparing a head lice shampoo, (Licener®) with an anti-head lice product containing dimethicone (Jacutin® Pedicul Fluid)

A new study conducted between July and November 2016 in households of two villages in Egypt compared the safety and efficacy of a shampoo-based head lice treatment (Licener®) with an anti-head lice product (Jacutin® Pedicul Fluid) via a randomized and controlled clinical study.

07.04.17 | A randomised clinical trial to evaluate the efficacy and safety of a new pediculicide made with saponified olive oil in the eradication of head lice.

A new study has compared the efficacy and safety of a new pediculicide, Inex Pediculicide Soap® with Paranix® via a randomised clinical trial involving children diagnosed with pediculosis and 6 paediatricians from the community of Madrid, Spain.

Site Map   |    Privacy Policy   |   Terms & Conditions

© 2012-2013 pediculosis.com — all rights reserved